XL092 is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values in cell-based assays of 15, 1.6, 3.4, and 7.2 nM respectively. In xenograft studies, XL092 caused substantial tumor growth inhibition following 10 mg/kg daily oral dosing for 14 days. XL092 has good oral bioavailability and a significantly shorter half-life than cabozantinib.
For research use only. We do not sell to patients.
Name | XL092 |
---|---|
Iupac Chemical Name | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- |
Synonyms | JUN04542; JUN-04542; JUN 04542; XL092; XL-092; X L092; Zanzalintinib |
Molecular Formula | C29H25FN4O5 |
Molecular Weight | 528.53 |
Smile | O=C(C1(C(NC2=CC=C(OC3=CC=NC4=CC(OC)=C(C(NC)=O)C=C34)C=C2)=O)CC1)NC5=CC=C(F)C=C5 |
InChiKey | JSPCKALGNNVYOO-UHFFFAOYSA-N |
InChi | InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37) |
CAS Number | 2367004-54-2 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% Min. |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |